AstraZeneca to pay $520 million in US Seroquel off-label probe
02 November 2009
Nancy Faigen
AstraZeneca has reached a $520 million agreement in principle to resolve an investigation by the Philadelphia office of the US Department of Justice into the company's sales and marketing practices for its antipsychotic Seroquel (quetiapine fumarate), including allegations that the company promoted...
Please Login to read the full article.
02 November 2009
Nancy Faigen
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Zombies, doomsday and debt ceilings, oh my
- US Capitol Capsule: Health reform extends Medicare solvency, but programme to go bust by 2024
- Merck paying $950 million to settle US Vioxx criminal, civil charges
- J&J pleads guilty in off-label promotion scheme for Natrecor; fined $85m
ANALYSIS
Other Informa Analysis
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
